The Eleanor ncRNAs activate the topological domain of the ESR1 locus to balance against apoptosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
22 08 2019
Historique:
received: 22 06 2018
accepted: 08 07 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 1 1 2020
Statut: epublish

Résumé

MCF7 cells acquire estrogen-independent proliferation after long-term estrogen deprivation (LTED), which recapitulates endocrine therapy resistance. LTED cells can become primed for apoptosis, but the underlying mechanism is largely unknown. We previously reported that Eleanor non-coding RNAs (ncRNAs) upregulate the ESR1 gene in LTED cells. Here, we show that Eleanors delineate the topologically associating domain (TAD) of the ESR1 locus in the active nuclear compartment of LTED cells. The TAD interacts with another transcriptionally active TAD, which is 42.9 Mb away from ESR1 and contains a gene encoding the apoptotic transcription factor FOXO3. Inhibition of a promoter-associated Eleanor suppresses all genes inside the Eleanor TAD and the long-range interaction between the two TADs, but keeps FOXO3 active to facilitate apoptosis in LTED cells. These data indicate a role of ncRNAs in chromatin domain regulation, which may underlie the apoptosis-prone nature of therapy-resistant breast cancer cells and could be good therapeutic targets.

Identifiants

pubmed: 31439835
doi: 10.1038/s41467-019-11378-4
pii: 10.1038/s41467-019-11378-4
pmc: PMC6706407
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Aromatase Inhibitors 0
Chromatin 0
ESR1 protein, human 0
Estrogen Receptor alpha 0
Estrogens 0
FOXO3 protein, human 0
Forkhead Box Protein O3 0
RNA, Untranslated 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3778

Références

Nat Methods. 2012 Oct;9(10):969-72
pubmed: 22961246
PLoS One. 2014 May 23;9(5):e98207
pubmed: 24858012
Br J Cancer. 2013 Sep 17;109(6):1537-42
pubmed: 24002591
Genome Biol. 2015 Aug 28;16:180
pubmed: 26316348
Nucleic Acids Res. 2016 Aug 19;44(14):6625-38
pubmed: 27378773
Trends Genet. 2017 Jun;33(6):375-377
pubmed: 28359583
Apoptosis. 2005 May;10(3):667-78
pubmed: 15909128
Nat Rev Cancer. 2007 Nov;7(11):847-59
pubmed: 17943136
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S61-73
pubmed: 16113100
Nat Methods. 2007 Nov;4(11):895-901
pubmed: 17971780
Nat Rev Cancer. 2002 Feb;2(2):101-12
pubmed: 12635173
Nat Commun. 2018 Apr 11;9(1):1387
pubmed: 29643333
Science. 2009 Oct 9;326(5950):289-93
pubmed: 19815776
Science. 2008 Dec 12;322(5908):1717-20
pubmed: 18988810
Nat Commun. 2015 Apr 29;6:6966
pubmed: 25923108
Nat Rev Cancer. 2009 Sep;9(9):631-43
pubmed: 19701242
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Cancer Res. 1987 Aug 15;47(16):4355-60
pubmed: 3607768
Mol Cell Biol. 2007 Jan;27(1):384-94
pubmed: 17043109
Cell. 2014 Dec 18;159(7):1665-80
pubmed: 25497547
Breast Cancer Res Treat. 2011 Aug;129(1):11-21
pubmed: 21336599
Cell Syst. 2016 Jul;3(1):95-8
pubmed: 27467249
Cell. 2017 Sep 21;171(1):103-119.e18
pubmed: 28938112
Oncogene. 2010 Nov 11;29(45):6071-83
pubmed: 20711236
Mol Cell Biol. 2010 Feb;30(3):857-70
pubmed: 19933843
Cell Rep. 2016 May 31;15(9):2038-49
pubmed: 27210764
Genome Biol. 2018 Mar 15;19(1):32
pubmed: 29540241
Blood. 2007 Nov 1;110(9):3209-17
pubmed: 17634411
Science. 2008 Dec 19;322(5909):1845-8
pubmed: 19056941
Methods Mol Biol. 2018;1861:221-245
pubmed: 30218370
Endocrinology. 1998 Oct;139(10):4164-74
pubmed: 9751496
Nat Med. 2011 Jun;17(6):660-1
pubmed: 21647142
Nat Struct Mol Biol. 2011 Mar;18(3):372-8
pubmed: 21336277
Genome Biol. 2018 Oct 4;19(1):151
pubmed: 30286773
Cell. 2017 May 18;169(5):930-944.e22
pubmed: 28525758
BMC Cancer. 2015 Oct 15;15:702
pubmed: 26470790
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86
pubmed: 22011582
Nature. 2011 Apr 7;472(7341):120-4
pubmed: 21423168
Nat Med. 2011 Jun;17(6):715-9
pubmed: 21602804
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nature. 2012 Apr 11;485(7398):381-5
pubmed: 22495304
BMC Bioinformatics. 2018 Jul 31;19(1):279
pubmed: 30064362
J Natl Cancer Inst. 2001 Nov 21;93(22):1714-23
pubmed: 11717332
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Cell Biol. 2004 Oct;24(19):8681-90
pubmed: 15367686
Trends Mol Med. 2018 Mar;24(3):257-277
pubmed: 29449148
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Curr Opin Cell Biol. 2019 Jun;58:26-33
pubmed: 30682683
J Cell Sci. 2007 Aug 15;120(Pt 16):2755-61
pubmed: 17690303
Hum Mol Genet. 2010 Oct 15;19(R2):R162-8
pubmed: 20798109
Breast Cancer Res. 2008;10(1):R21
pubmed: 18312651
Wiley Interdiscip Rev RNA. 2017 Mar;8(2):
pubmed: 27489248
Development. 2013 Mar;140(6):1184-95
pubmed: 23444351
J Biol Chem. 2004 Jan 9;279(2):1513-25
pubmed: 14551207
Science. 2008 Dec 19;322(5909):1851-4
pubmed: 19056938
Breast Cancer Res Treat. 2001 May;67(2):111-6
pubmed: 11519859
EMBO J. 2013 Dec 11;32(24):3119-29
pubmed: 24185899
Nature. 2011 May 15;474(7351):390-4
pubmed: 21572438
Nature. 2012 Apr 11;485(7398):376-80
pubmed: 22495300
N Engl J Med. 2006 Jan 19;354(3):270-82
pubmed: 16421368
Genome Biol. 2015 Sep 28;16:214
pubmed: 26415882
Science. 2008 Dec 19;322(5909):1849-51
pubmed: 19056940
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
PLoS One. 2013 Aug 13;8(8):e70746
pubmed: 23967095
Nature. 2017 Nov 2;551(7678):51-56
pubmed: 29094699
Eur J Cancer Clin Oncol. 1987 Dec;23(12):1935-9
pubmed: 3436356
J Steroid Biochem Mol Biol. 1997 Jun;62(2-3):155-63
pubmed: 9393950
Sci Rep. 2018 Oct 12;8(1):15202
pubmed: 30315184

Auteurs

Mohamed Osama Ali Abdalla (MOA)

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan.
Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, 41522, Egypt.

Tatsuro Yamamoto (T)

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan.
Division of Cancer Biology, The Cancer Institute of JFCR, Tokyo, 135-8550, Japan.
Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Kazumitsu Maehara (K)

Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan.

Jumpei Nogami (J)

Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan.

Yasuyuki Ohkawa (Y)

Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan.

Hisashi Miura (H)

Laboratory for Developmental Epigenetics, RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, 650-0047, Japan.

Rawin Poonperm (R)

Laboratory for Developmental Epigenetics, RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, 650-0047, Japan.

Ichiro Hiratani (I)

Laboratory for Developmental Epigenetics, RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, 650-0047, Japan.

Hideki Nakayama (H)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Mitsuyoshi Nakao (M)

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan. mnakao@gpo.kumamoto-u.ac.jp.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, 104-0004, Japan. mnakao@gpo.kumamoto-u.ac.jp.

Noriko Saitoh (N)

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan. noriko.saito@jfcr.or.jp.
Division of Cancer Biology, The Cancer Institute of JFCR, Tokyo, 135-8550, Japan. noriko.saito@jfcr.or.jp.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH